NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

23.07M

Vuru Grade

31.66/100

Current Price

$2.52
+0.1201 (+5.0042%)

Company Metrics

  • P/E 0
  • P/S 3.9499
  • P/B 27.9
  • EPS -5.9540
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / N/A %
  • Avg. Vol. 30,506.00
  • Shares 2.78M
  • Market Cap. 23.07M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 06/13/16; Press Release. NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer.
NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
Our team of financial professionals can help you plan and save for retirement, then live well in it. /conga/kiosk/retirementors.html 361307.
NovaBay Pharmaceuticals, Inc. (NBY) Falls in Pre-market Before Skyrocketing ...
Independent Reporter - Dec 21, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) fell considerably in pre-market trading this morning, before skyrocking after the market opened.
This Weeks Broker Views For NovaBay Pharmaceuticals, Inc. (NBY)
Fiscal Standard - Jun 19, 2016
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market.
NovaBay Pharma (NBY) Names Mark Sieczkarek as Permanent CEO
StreetInsider.com - Jun 13, 2016
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announces the appointment of Mark M. Sieczkarek as President and Chief Executive Officer, effectively immediately.
NovaBay appoints Mark M. Sieczkarek as President and CEO - Seeking Alpha
Broker Changes For NovaBay Pharmaceuticals, Inc. (NBY) - Risers & Fallers
NovaBay Pharmaceuticals Announces Partnership with ALPHAEON to Bring Avenova ...
Business Wire (press release) - Sep 24, 2015
IRVINE, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--ALPHAEON Corporation and NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that they have formed a partnership that will add NovaBay's breakthrough Avenova to the products ...
NovaBay Pharma inks deal with Alphaeon to sell Avenova on social network ShoutMD - Seeking Alpha
NovaBay Pharma (NBY), ALPHAEON Enter Partnership Covering Avenova - StreetInsider.com
NovaBay Pharmaceuticals, Inc. (NBY) Latest Broker Views
Risers & Fallers - Jun 1, 2016
A number of investment brokers have recently updated their price targets on shares of NovaBay Pharmaceuticals, Inc. (NBY).
Next Weeks Broker Price Targets For NovaBay Pharmaceuticals, Inc. (NBY)
Fiscal Standard - Jun 24, 2016
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market.
NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova ...
Business Wire (press release) - Nov 19, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) announces a corporate restructuring to focus on the commercialization of its prescription Avenova® Lid and Lash Cleanser. NovaBay is also taking steps to reduce operating expenses ...
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K
Business Wire (press release) - Mar 22, 2016
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) (the “Company”) announces that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2015, included in the Company's Annual Report on Form ...